Improved delivery of the anticancer agent citral using BSA nanoparticles and polymeric wafers

Benjamin White,1 Anna Evison,1 Eszter Dombi,1 Helen E Townley1,2 1Nuffield Department of Obstetrics and Gynaecology, Women’s Centre, John Radcliffe Hospital, 2Department of Engineering Science, Oxford University, Oxford, UK Abstract: Rhabdomyosarcoma (RMS) is the most common soft tissue sa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	White B, Evison A, Dombi E, Townley HE
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Medical technology R855-855.5 Chemical technology TP1-1185
Acceso en línea:	https://doaj.org/article/a7e9bf07be644b07993056d6c9e973a8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a7e9bf07be644b07993056d6c9e973a8
record_format	dspace
spelling	oai:doaj.org-article:a7e9bf07be644b07993056d6c9e973a82021-12-02T03:50:36ZImproved delivery of the anticancer agent citral using BSA nanoparticles and polymeric wafers1177-8903https://doaj.org/article/a7e9bf07be644b07993056d6c9e973a82017-12-01T00:00:00Zhttps://www.dovepress.com/improved-delivery-of-the-anticancer-agent-citral-using-bsa-nanoparticl-peer-reviewed-article-NSAhttps://doaj.org/toc/1177-8903Benjamin White,1 Anna Evison,1 Eszter Dombi,1 Helen E Townley1,2 1Nuffield Department of Obstetrics and Gynaecology, Women’s Centre, John Radcliffe Hospital, 2Department of Engineering Science, Oxford University, Oxford, UK Abstract: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, with a 5-year survival rate of between 30 and 65%. Standard treatment involves surgery, radiation treatment, and chemotherapy. However, there is a high recurrence rate, particularly from locoregional spread. We investigated the use of the natural compound citral (3,7-dimethyl-2,6-octadienal), which can be found in a number of plants, but is particularly abundant in lemon grass (Cymbopogon citratus) oil, for activity against immortalized RMS cells. Significant cancer cell death was seen at concentrations above 150 μM citral, and mitochondrial morphological changes were seen after incubation with 10 μM citral. However, since citral is a highly volatile molecule, we prepared albumin particles by a desolvation method to encapsulate citral, as a means of stabilization. We then further incorporated the loaded nanoparticles into a biodegradable polyanhydride wafer to generate a slow release system. The wafers were shown to degrade by 50% over the course of 25 days and to release the active compound. We therefore propose the use of the citral-nanoparticle-polymer wafers for implantation into the tumor bed after surgical removal of a sarcoma as a means to control locoregional spread due to any remaining cancerous cells. Keywords: citral, nanoparticle, wafer, biodegradable, mitochondria, toroidal, cancer, rhabdomyosarcoma, Cymbopogon citratusWhite BEvison ADombi ETownley HEDove Medical PressarticleMedical technologyR855-855.5Chemical technologyTP1-1185ENNanotechnology, Science and Applications, Vol Volume 10, Pp 163-175 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medical technology R855-855.5 Chemical technology TP1-1185
spellingShingle	Medical technology R855-855.5 Chemical technology TP1-1185 White B Evison A Dombi E Townley HE Improved delivery of the anticancer agent citral using BSA nanoparticles and polymeric wafers
description	Benjamin White,1 Anna Evison,1 Eszter Dombi,1 Helen E Townley1,2 1Nuffield Department of Obstetrics and Gynaecology, Women’s Centre, John Radcliffe Hospital, 2Department of Engineering Science, Oxford University, Oxford, UK Abstract: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, with a 5-year survival rate of between 30 and 65%. Standard treatment involves surgery, radiation treatment, and chemotherapy. However, there is a high recurrence rate, particularly from locoregional spread. We investigated the use of the natural compound citral (3,7-dimethyl-2,6-octadienal), which can be found in a number of plants, but is particularly abundant in lemon grass (Cymbopogon citratus) oil, for activity against immortalized RMS cells. Significant cancer cell death was seen at concentrations above 150 μM citral, and mitochondrial morphological changes were seen after incubation with 10 μM citral. However, since citral is a highly volatile molecule, we prepared albumin particles by a desolvation method to encapsulate citral, as a means of stabilization. We then further incorporated the loaded nanoparticles into a biodegradable polyanhydride wafer to generate a slow release system. The wafers were shown to degrade by 50% over the course of 25 days and to release the active compound. We therefore propose the use of the citral-nanoparticle-polymer wafers for implantation into the tumor bed after surgical removal of a sarcoma as a means to control locoregional spread due to any remaining cancerous cells. Keywords: citral, nanoparticle, wafer, biodegradable, mitochondria, toroidal, cancer, rhabdomyosarcoma, Cymbopogon citratus
format	article
author	White B Evison A Dombi E Townley HE
author_facet	White B Evison A Dombi E Townley HE
author_sort	White B
title	Improved delivery of the anticancer agent citral using BSA nanoparticles and polymeric wafers
title_short	Improved delivery of the anticancer agent citral using BSA nanoparticles and polymeric wafers
title_full	Improved delivery of the anticancer agent citral using BSA nanoparticles and polymeric wafers
title_fullStr	Improved delivery of the anticancer agent citral using BSA nanoparticles and polymeric wafers
title_full_unstemmed	Improved delivery of the anticancer agent citral using BSA nanoparticles and polymeric wafers
title_sort	improved delivery of the anticancer agent citral using bsa nanoparticles and polymeric wafers
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/a7e9bf07be644b07993056d6c9e973a8
work_keys_str_mv	AT whiteb improveddeliveryoftheanticanceragentcitralusingbsananoparticlesandpolymericwafers AT evisona improveddeliveryoftheanticanceragentcitralusingbsananoparticlesandpolymericwafers AT dombie improveddeliveryoftheanticanceragentcitralusingbsananoparticlesandpolymericwafers AT townleyhe improveddeliveryoftheanticanceragentcitralusingbsananoparticlesandpolymericwafers
_version_	1718401609699950592

Improved delivery of the anticancer agent citral using BSA nanoparticles and polymeric wafers

Ejemplares similares